Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 11/2013

01-11-2013 | Letter

Impact of impaired insulin secretion and insulin resistance on the incidence of diabetes in a Japanese cohort

Authors: Keishi Yamauchi, Toru Aizawa

Published in: Diabetologia | Issue 11/2013

Login to get access

Excerpt

To the Editor: On the basis of the data obtained in a longitudinal study of 3,059 Japanese participants without diabetes at baseline, Morimoto et al [1] concluded that impaired insulin secretion (IIS) had a greater impact than insulin resistance (IR) on the incidence of type 2 diabetes in a Japanese population. We think that it would have been better to pay slightly more attention to the method of analysis and interpretation of the data, and that this might have significantly raised the impact of the article. …
Literature
1.
Morimoto A, Tatsumi Y, Deura K et al (2013) Impact of impaired insulin secretion and insulin resistance on the incidence of type 2 diabetes mellitus in a Japanese population: the Saku study. Diabetologia 56:1671–1679PubMedCrossRef
2.
Tataranni PA, Bogardus C (2004) Metabolic abnormalities in the development of type 2 diabetes mellitus. In: LeRoith D, Olefsky JM, Taylor SI (eds) Diabetes mellitus: a fundamental and clinical text, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 797–807
3.
Alsahli M, Gerich JE (2010) Abnormalities of insulin secretion and β-cell defects in type 2 diabetes. In: Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ (eds) Textbook of diabetes, 4th edn. Wiley-Blackwell, Chichester, pp 160–173CrossRef
4.
Tripathy D, Almgren P, Tuomi T, Groop L (2004) Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care 27:2204–2210PubMedCrossRef
5.
Lillioja S, Mott DM, Spraul M et al (1993) Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329:1988–1992PubMedCrossRef
6.
Faulenbach MV, Wright LA, Lorenzo C, et al (2013) Impact of differences in glucose tolerance on the prevalence of a negative insulinogenic index. J Diabetes Complications 27:158–161
7.
Utzschneider KM, Prigeon RL, Faulenbach MV et al (2009) Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32:335–341PubMedCrossRef
Metadata
Title
Impact of impaired insulin secretion and insulin resistance on the incidence of diabetes in a Japanese cohort
Authors
Keishi Yamauchi
Toru Aizawa
Publication date
01-11-2013
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 11/2013
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-013-3046-2

Other articles of this Issue 11/2013

Diabetologia 11/2013 Go to the issue

Article

Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway

Article

Downregulation of Sfrp5 promotes beta cell proliferation during obesity in the rat

Article

Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case–control study

Short Communication

Time trends in mortality rates in type 1 diabetes from 2002 to 2011

Article

A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction

Short Communication

Does metformin modify the effect on glycaemic control of aerobic exercise, resistance exercise or both?
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits